Protein expression analysis of ALCAM and CEACAM6 in breast cancer metastases reveals significantly increased ALCAM expression in metastases of the skin

AimsFor prediction and understanding of underlying mechanisms of organ-specific metastases, various gene and protein expression signatures have been identified in primary breast carcinomas. These expression signatures often include several genes coding for adhesion molecules, such as activated leuco...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical pathology Vol. 64; no. 2; pp. 146 - 152
Main Authors Ihnen, Maike, Kilic, Ergin, Köhler, Nadine, Löning, Thomas, Witzel, Isabell, Hagel, Christian, Höller, Sylvia, Kersten, Jan F, Müller, Volkmar, Jänicke, Fritz, Milde-Langosch, Karin
Format Journal Article
LanguageEnglish
Published London BMJ Publishing Group Ltd and Association of Clinical Pathologists 01.02.2011
BMJ Publishing Group
BMJ Publishing Group LTD
Subjects
Online AccessGet full text
ISSN0021-9746
1472-4146
1472-4146
DOI10.1136/jcp.2010.082602

Cover

More Information
Summary:AimsFor prediction and understanding of underlying mechanisms of organ-specific metastases, various gene and protein expression signatures have been identified in primary breast carcinomas. These expression signatures often include several genes coding for adhesion molecules, such as activated leucocyte cell adhesion molecule (ALCAM/CD166) and carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), both of which may play an important role in the development of distant metastases because of their adherent properties. Owing to their predominantly membranous localisation, they are also considered to have certain therapeutic potential. Apart from expression data obtained in the primary tumour, data for gene and protein expression patterns in distant breast cancer metastases are rare. Therefore this study focuses on analysing the distribution of ALCAM and CEACAM6 protein expression in breast cancer metastases from different sites.MethodsImmunohistochemical staining for ALCAM and CEACAM6 in 117 breast cancer metastases derived from liver (n=24), lung (n=19), brain (n=21), bone (n=36) and skin (n=17) was performed.ResultsImmunoreactive scores (IRS) for ALCAM in all metastases except skin metastases ranged from 2.63 to 5.10 (membranous) and 2.79 to 3.67 (cytoplasmic), showing a positive correlation with each other (r=0.690, p<0.001). In skin metastases, ALCAM expression was significantly stronger (membranous IRS, 8.76; cytoplasmic IRS, 7.12; p<0.001). Mean staining intensity for CEACAM6 was IRS 3.88. No or weak CEACAM6 and ALCAM staining (IRS 0–3) was seen in 53% vs 27% of all metastases.ConclusionsCompared with CEACAM6, ALCAM showed significantly stronger protein expression in breast cancer skin metastases compared with metastases in all other sites.
Bibliography:istex:7016B82E4DFF9B740A7069BAA80C873251A85A32
local:jclinpath;64/2/146
ark:/67375/NVC-03ST8XD8-B
MI and EK contributed equally.
href:jclinpath-64-146.pdf
ArticleID:jclinpath82602
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0021-9746
1472-4146
1472-4146
DOI:10.1136/jcp.2010.082602